Compositions and methods for treating multiple sclerosis
AssigneeCentre for Addiction and Mental Health
InventorFang Liu
Life of this patent
Estimating the term…
Abstract
Disclosed are polypeptides, compositions and methods for the treatment or prophylaxis of multiple sclerosis. The method involves the steps of administering a polypeptide, or nucleic acid encoding the polypeptide, comprising the GluR2 NTal-3-2 (Y142-K172) amino acid sequence as shown by SEQ ID NO:1 or SEQ ID NO:5 to a subject in need of the treatment.
Claims21
A method for supressing macrophage infiltration, microglia activation or infiltration of leukocytes in the central nervous system (CNS) of a subject that exhibits multiple sclerosis-like symptoms of axonal damage, oligodendrocyte death, demyelination or a combination thereof comprising administering a polypeptide (a) comprising Asp153-Lys172 of the GluR2 N-terminus (DSDRGLSTLQAVLDSAAEKK (SEQ ID NO:5)) and wherein the polypeptide does not comprise SEQ ID NO:1 or (b) of between 31 and 200 amino acids comprising a GluR2 NT1-3-2 (Y142-K172) amino acid sequence defined by SEQ ID NO:1 to the subject to suppress macrophage infiltration, microglia activation or infiltration of leukocytes in the CNS of the subject.
A method for supressing macrophage infiltration, microglia activation or infiltration of leukocytes in the central nervous system (CNS) of a subject that exhibits multiple sclerosis-like symptoms of axonal damage, oligodendrocyte death, demyelination or a combination thereof comprising administering a composition comprising a polypeptide (a) comprising Asp153-Lys172 of the GluR2 N-terminus (DSDRGLSTLQAVLDSAAEKK (SEQ ID NO:5)) and wherein the polypeptide does not comprise SEQ ID NO:1 or (b) of between 31 and 200 amino acids comprising a GluR2 NT1-3-2 (Y142-K172) amino acid sequence defined by SEQ ID NO:1 to the subject to suppress macrophage infiltration, microglia activation or infiltration of leukocytes in the CNS of the subject.
A method for supressing macrophage infiltration, microglia activation or infiltration of leukocytes in the central nervous system (CNS) of a subject that exhibits multiple sclerosis-like symptoms of axonal damage, oligodendrocyte death, demyelination or a combination thereof comprising administering a polypeptide (a) comprising Asp153-Lys172 of the GluR2 N-terminus (DSDRGLSTLQAVLDSAAEKK (SEQ ID NO:5)) and wherein the polypeptide does not comprise SEQ ID NO:1 or (b) of between 31 and 200 amino acids comprising a GluR2 NT1-3-2 (Y142-K172) amino acid sequence defined by SEQ ID NO:1 to the subject to suppress macrophage infiltration, microglia activation or infiltration of leukocytes in the CNS of the subject, and wherein the method increases neuronal survival in the subject.
Dependencies are inferred from the claim text.